Is NEPHROCARE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NEPHROCARE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NEPHROCARE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NEPHROCARE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NEPHROCARE?
Key metric: As NEPHROCARE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for NEPHROCARE. This is calculated by dividing NEPHROCARE's market cap by their current
earnings.
What is NEPHROCARE's PE Ratio?
PE Ratio
82.7x
Earnings
₹44.11m
Market Cap
₹3.65b
NEPHROCARE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue
13.3x
Enterprise Value/EBITDA
55.1x
PEG Ratio
n/a
Price to Earnings Ratio vs Peers
How does NEPHROCARE's PE Ratio compare to its peers?
The above table shows the PE ratio for NEPHROCARE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Price-To-Earnings vs Industry: NEPHROCARE is expensive based on its Price-To-Earnings Ratio (82.7x) compared to the Indian Healthcare industry average (42.6x).
Price to Earnings Ratio vs Fair Ratio
What is NEPHROCARE's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
NEPHROCARE PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
82.7x
Fair PE Ratio
n/a
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NEPHROCARE's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.